Literature DB >> 33435987

Circular RNA circ_0081001 knockdown enhances methotrexate sensitivity in osteosarcoma cells by regulating miR-494-3p/TGM2 axis.

Wei Wei1, Liefeng Ji2, Wanli Duan2, Jiang Zhu2.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) have been shown to participate in the chemoresistance and tumorigenesis of multiple cancers. The purpose of this research was to investigate the function of circ_0081001 in methotrexate (MTX) resistance of osteosarcoma (OS) and its potential molecular mechanism.
METHODS: The expression of circ_0081001, cytochrome P450 family 51 subfamily A member 1 (CYP51A1), and miR-494-3p was detected by qRT-PCR. Cell viability, apoptosis, migration, and invasion were evaluated by Cell Counting Kit-8 (CCK-8) assay, flow cytometry, and transwell assay, respectively. Western blot (WB) assay was used to measure the protein levels of cleaved-caspase3 (cleaved-casp3), E-cadherin, N-cadherin, and transglutaminase-2 (TGM2). The interaction between miR-494-3p and circ_0081001 or TGM2 was predicted by bioinformatics analysis and verified using the dual-luciferase reporter assay. The mice xenograft model was established to investigate the roles of circ_0081001 in MTX resistance of OS in vivo.
RESULTS: Circ_0081001 and TGM2 were upregulated, and miR-494-3p was downregulated in MTX-resistant OS tissues and cells. Moreover, circ_0081001 interference enhanced cell sensitivity to MTX through promoting apoptosis and inhibiting cell viability and metastasis in vitro. Furthermore, circ_0081001 was identified as a molecular sponge of miR-494-3p to upregulate TGM2 level. In addition, circ_0081001 knockdown inhibited MTX resistance via upregulating miR-494-3p and downregulating TGM2. Besides, circ_0081001 downregulation improved MTX sensitivity of OS in vivo.
CONCLUSION: Knockdown of circ_0081001 enhanced MTX sensitivity of OS cells through downregulating TGM2 by sponging miR-494-3p, elucidating a novel regulatory mechanism for chemoresistance of OS and providing a potential circRNA-targeted therapy for OS.

Entities:  

Keywords:  MTX sensitivity; TGM2; circ_0081001; miR-494-3p

Mesh:

Substances:

Year:  2021        PMID: 33435987      PMCID: PMC7805151          DOI: 10.1186/s13018-020-02169-5

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


  39 in total

1.  Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR-1253/FOXF1 pathway.

Authors:  Lipeng Huang; Mangmang Chen; Jun Pan; Weiyang Yu
Journal:  Biochem Biophys Res Commun       Date:  2018-04-21       Impact factor: 3.575

2.  Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma.

Authors:  Daniel G Fuja; Nino C Rainusso; Ryan L Shuck; Lyazat Kurenbekova; Lawrence A Donehower; Jason T Yustein
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

3.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.

Authors:  Gaetano Bacci; Alessandra Longhi; Michela Versari; Mario Mercuri; Antonio Briccoli; Piero Picci
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

4.  miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.

Authors:  Lingqin Song; Di Liu; Baofeng Wang; Jianjun He; Shuqun Zhang; Zhijun Dai; Xiaobin Ma; Xijing Wang
Journal:  Oncol Rep       Date:  2015-05-08       Impact factor: 3.906

5.  Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells.

Authors:  Mi Kyung Park; Seung Ho Jo; Hye Ja Lee; June Hee Kang; You Ri Kim; Hyun Ji Kim; Eun Ji Lee; Jae Young Koh; Kyung Ok Ahn; Kyung Chae Jung; Seung Hyun Oh; Soo Youl Kim; Chang Hoon Lee
Journal:  Life Sci       Date:  2012-11-28       Impact factor: 5.037

6.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

7.  miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells.

Authors:  Xue-Tao Li; Hang-Zhou Wang; Zhi-Wu Wu; Tian-Quan Yang; Zhao-Hui Zhao; Gui-Lin Chen; Xue-Shun Xie; Bin Li; Yong-Xin Wei; Yu-Lun Huang; You-Xin Zhou; Zi-Wei Du
Journal:  Cell Mol Neurobiol       Date:  2015-02-08       Impact factor: 5.046

8.  miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma.

Authors:  Wei Yuan; Du Wang; Yang Liu; Dongdong Tian; Yang Wang; Ranxi Zhang; Liangjun Yin; Zhongliang Deng
Journal:  Mol Med Rep       Date:  2017-10-04       Impact factor: 2.952

9.  Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.

Authors:  Zhu Kun-Peng; Ma Xiao-Long; Zhang Chun-Lin
Journal:  Int J Biol Sci       Date:  2018-02-12       Impact factor: 6.580

10.  MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN.

Authors:  Hui Lin; Zhi-Ping Huang; Jiao Liu; Yun Qiu; Yuan-Ping Tao; Meng-Chao Wang; Hui Yao; Ke-Zhu Hou; Fang-Ming Gu; Xuan-Fu Xu
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more
  7 in total

1.  CircFBXW7 inhibits the tumorigenesis of T-cell acute lymphoblastic leukemia through modulating miR-494-3p/SOX1 axis.

Authors:  Cong Luo; Jun-Jun Li; Feng Wen; Yi-Xiong Cao; Ze-Yu Luo; Xing-Xing Long
Journal:  Cell Death Discov       Date:  2022-05-10

Review 2.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 3.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 4.  Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.

Authors:  Jingyu Zhong; Guangcheng Zhang; Weiwu Yao
Journal:  J Orthop Surg Res       Date:  2021-10-07       Impact factor: 2.359

5.  CircRNA 0009043 suppresses non-small-cell lung cancer development via targeting the miR-148a-3p/DNAJB4 axis.

Authors:  Kelin She; Shaoqi Yu; Shushuai He; Wen Wang; Biao Chen
Journal:  Biomark Res       Date:  2022-08-16

Review 6.  An overview of resistance to chemotherapy in osteosarcoma and future perspectives.

Authors:  Dorian Yarih Garcia-Ortega; Sara Aileen Cabrera-Nieto; Haydee Sarai Caro-Sánchez; Marlid Cruz-Ramos
Journal:  Cancer Drug Resist       Date:  2022-06-23

Review 7.  MicroRNA as a Potential Therapeutic Molecule in Cancer.

Authors:  Joanna Szczepanek; Monika Skorupa; Andrzej Tretyn
Journal:  Cells       Date:  2022-03-16       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.